JBJan Bruha

Jan Bruha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jan Bruha has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Advancing Early Diagnosis of Colorectal Anastomotic Leakage Using Drain Fluid Biochemical Analysis

    by Robert Polak, Prokop Pavel, Rosendorf Jachym, Molacek Jiri, Palek Richard, Vycital Ondrej, Bruha Jan, Rajdl Daniel, Liska Vaclav

    Anastomotic leakage is a common and very serious complication in colorectal surgery. While minor leaks can often be managed conservatively, advanced leaks with peritonitis require surgical reintervention. Leakage is frequently diagnosed late, which we attribute to the absence of an effective screening method and a standardized postoperative protocol. The current classification of leaks is predominantly retrospective and descriptive, offering limited clinical utility. Our goal is to develop a functional postoperative protocol, and a new clinical classification of leaks. In this initial study, we focused on advancing early diagnosis of leakage, by incorporating biochemical analysis of drain fluids. As early markers we chose Calprotectin, Neopterin and D-Lactate. We included 96 patients into this study. We analyzed the drainage fluids during the first postoperative days and compared concentrations of markers between groups with and without leakage. We proved a statistically significant difference in concentrations and its dynamics in the first postoperative days in calprotectin in the leakage group. We further report a statistically significant difference in concentration of calprotectin on the 5th postoperative day, and of Neopterin on the 4th and 5th postoperative days in the leakage group. Taken together, these results suggest promise for calprotectin and neopterin as diagnostic biomarkers.

  • Open Access

    The Associations of Selenoprotein Genetic Variants with the Risks of Colorectal Adenoma and Colorectal Cancer: Case–Control Studies in Irish and Czech Populations

    by Maryam Mukhtar, Niall Ashfield, Ludmila Vodickova, Veronika Vymetalkova, Miroslav Levy, Václav Liska, Jan Bruha, Petra Bendova, Jacintha O’sullivan, Glen Doherty, et al.

    Background: Selenium manifests its biological effects through its incorporation into selenoproteins, which play several roles in countering oxidative and inflammatory responses implicated in colorectal carcinogenesis. Selenoprotein genetic variants may contribute to colorectal cancer (CRC) development, as we previously observed for SNP variants in a large European prospective study and a Czech case–control cohort. Methods: We tested if significantly associated selenoprotein gene SNPs from these studies were also associated with CRC risk in case–control studies from Ireland (colorectal neoplasia, i.e., cancer and adenoma cases: 450, controls: 461) and the Czech Republic (CRC cases: 718, controls: 646). Genotyping of 23 SNPs (20 in the Irish and 13 in the Czechs) was performed by competitive specific allele-specific PCR (KASPar). Multivariable adjusted logistic regression was used to assess the associations with CRC development. Results: We found significant associations with an increased CRC risk for rs5859 (SELENOF) and rs2972994 (SELENOP) in the Irish cohort but only with rs4802034 (SELENOV) in the Czechs. Significant associations were observed for rs5859 (SELENOF), rs4659382 (SELENON), rs2972994 (SELENOP), rs34713741 (SELENOS), and the related Se metabolism gene variant rs2275129 (SEPHS1) with advanced colorectal neoplasia development. However, none of these findings retained significance after multiple testing corrections. Conclusions: Several SNPs previously associated with CRC risk were also associated with CRC or colorectal neoplasia development in either the Irish or Czech cohorts. Selenoprotein gene variation may modify CRC risk across diverse European populations, although the specific variants may differ.


  • Open Access

    Circulating Tumor Cell Kinetics and Morphology from the Liquid Biopsy Predict Disease Progression in Patients with Metastatic Colorectal Cancer Following Resection

    by Drahomír Kolenčík, Sachin Narayan, Jana-Aletta Thiele, Dillon McKinley, Anna Sandström Gerdtsson, Lisa Welter, Petr Hošek, Pavel Ostašov, Ondřej Vyčítal, Jan Brůha, et al.

    The liquid biopsy has the potential to improve current clinical practice in oncology by providing real-time personalized information about a patient’s disease status and response to treatment. In this study, we evaluated 161 peripheral blood (PB) samples that were collected around surgical resection from 47 metastatic colorectal cancer (mCRC) patients using the High-Definition Single Cell Assay (HDSCA) workflow. In conjunction with the standard circulating tumor cell (CTC) enumeration, cellular morphology and kinetics between time-points of collection were considered in the survival analysis. CTCs, CTC-Apoptotic, and CTC clusters were found to indicate poor survival with an increase in cell count from pre-resection to post-resection. This study demonstrates that CTC subcategorization based on morphological differences leads to nuanced results between the subtypes, emphasizing the heterogeneity within the CTC classification. Furthermore, we show that factoring in the time-point of each blood collection is critical, both for its static enumeration and for the change in cell populations between draws. By integrating morphology and time-based analysis alongside standard CTC enumeration, liquid biopsy platforms can provide greater insight into the pathophysiology of mCRC by highlighting the complexity of the disease across a patient’s treatment.


  • Open Access

    Mesenchymal Stromal Cell Therapy in Novel Porcine Model of Diffuse Liver Damage Induced by Repeated Biliary Obstruction

    by Lucie Vištejnová, Václav Liška, Arvind Kumar, Jana Křečková, Ondřej Vyčítal, Jan Brůha, Jan Beneš, Yaroslav Kolinko, Tereza Blassová, Zbyněk Tonar, et al.

    In liver surgery, biliary obstruction can lead to secondary biliary cirrhosis, a life-threatening disease with liver transplantation as the only curative treatment option. Mesenchymal stromal cells (MSC) have been shown to improve liver function in both acute and chronic liver disease models. This study evaluated the effect of allogenic MSC transplantation in a large animal model of repeated biliary obstruction followed by partial hepatectomy. MSC transplantation supported the growth of regenerated liver tissue after 14 days (MSC group, n = 10: from 1087 ± 108 (0 h) to 1243 ± 92 mL (14 days); control group, n = 11: from 1080 ± 95 (0 h) to 1100 ± 105 mL (14 days), p = 0.016), with a lower volume fraction of hepatocytes in regenerated liver tissue compared to resected liver tissue (59.5 ± 10.2% vs. 70.2 ± 5.6%, p < 0.05). Volume fraction of connective tissue, blood vessels and bile vessels in regenerated liver tissue, serum levels of liver enzymes (AST, ALT, ALP and GGT) and liver metabolites (albumin, bilirubin, urea and creatinine), as well as plasma levels of IL-6, IL-8, TNF-α and TGF-β, were not affected by MSC transplantation. In our novel, large animal (pig) model of repeated biliary obstruction followed by partial hepatectomy, MSC transplantation promoted growth of liver tissue without any effect on liver function. This study underscores the importance of translating results between small and large animal models as well as the careful translation of results from animal model into human medicine.


  • Open Access

    lncRNAs in Non-Malignant Tissue Have Prognostic Value in Colorectal Cancer

    by Jana-Aletta Thiele, Petr Hosek, Eva Kralovcova, Pavel Ostasov, Vaclav Liska, Jan Bruha, Ondrej Vycital, Jachym Rosendorf, Alena Opattova, Josef Horak, et al.

    Although colorectal cancer (CRC) is the third most frequent cause of cancer related death in Europe, clinically relevant biomarkers for therapy guidance and prognosis are insufficiently reliable. Long non-coding RNAs (lncRNAs) are RNAs over 200 nucleotides long that are not translated into proteins but can influence biological processes. There is emerging evidence for their involvement in solid cancer as oncogenes, tumour suppressors or regulators of cell proliferation and metastasis development. The goal of this study was to evaluate the prognostic effect of selected lncRNAs in a retrospective study on CRC patients from the Czech Republic. We used a quantitative PCR approach to measure the expression in paired non-malignant and tumour tissue samples of CRC patients of nine lncRNAs previously shown to be involved in cancer progression—ANRIL, CCAT1, GAS5, linc-ROR, MALAT1, MIR155HG, PCAT1, SPRY4-IT1 and TUG1. Associations between expression and expression ratios and clinical characteristics and survival were assessed by using univariable Cox proportional hazards models, Kaplan-Meier estimations with the Gehan-Wilcoxon test, the Mann-Whitney U test, the Kruskal-Wallis test and Spearman’s correlations. A comparison of expression in tumour tissue (TT) and non-malignant mucosa tissue (MT) showed significant upregulation of CCAT1 and linc-ROR in TT (p < 0.001 and p = 0.001, respectively) and downregulation of ANRIL, MIR155HG and MALAT1 (p = 0.001, p = 0.010, p = 0.001, respectively). Linc-ROR was significantly associated with the presence of synchronous metastases (p = 0.033). For individual tissue types, lower MIR155HG expression in TT was correlated with both shorter overall survival (p = 0.008) and shorter disease-free survival (p = 0.040). In MT, expression ratios of CCAT1/ANRIL and CCAT1/MIR155HG were associated with overall survival (p = 0.005 and p = 0.006, respectively). Our results revealed that changes in expression of lncRNAs between MT and TT hold potential to be used as prognostic biomarkers in CRC patients. Moreover, the ratios of CCAT1 to ANRIL and MIR155HG in MT also exhibit potential for prognosis assessment without tumour sampling. Our results also indicate that cancer progression is associated with detrimental system-wide changes in patient tissue, which might govern patient survival even after successful elimination of tumour or cancerous cells.


  • Open Access

    Liver Parenchyma Regeneration in Connection with Extended Surgical Procedure - Experiment on Large Animal

    by Vaclav Liska, Vladislav Treska, Hynek Mirka, Ondrej Vycital, Jan Bruha, Pavel Pitule, Jana Kopalova, Tomas Skalicky, Alan Sutnar, Jan Benes, et al.